--- a
+++ b/clusters/9knumclustersv2/clust_1549.txt
@@ -0,0 +1,49 @@
+Other invasive malignancy within  years.
+Prior breast cancer or other invasive malignancy treated within  years
+Prior invasive malignancy of other histology currently requiring treatment
+In patients with a prior history of invasive malignancy, less than five years in complete remission
+Prior breast cancer or other invasive malignancy treated within  years
+For part B and part C, Presence of other active invasive cancers other than NSCLC or history of treatment for invasive cancer other than NSCLC in the past  years. Exceptions are:
+COHORT : HORMONE RECEPTOR POSITIVE BREAST CANCER: Patients with a history of another invasive malignancy within the last  years
+COHORT : ENDOMETRIAL CANCER: Patients with a history of another invasive malignancy within the last  years
+Prior therapy for glioblastoma or other invasive malignancy
+Have had or are planning to have the following invasive procedures:
+Evidence of other active invasive malignancy requiring treatment other than surgery in the past  years
+Other invasive malignancies within past  years from date of registration
+Other invasive malignancies within the past  years from date of registration
+Prior history of invasive malignancy within the last  years
+Concurrent active invasive malignancy or one previously diagnosed with a greater than % chance of recurrence in the next two years
+EXCLUSION CRITERIA FOR REGISTRATION: concurrent active invasive malignancy or one previously diagnosed with a greater than % chance of recurrence in the next two years
+Have had or are planning to have the following invasive procedures:
+Other active invasive malignancy; history of non-invasive malignancies such as ductal carcinoma in situ of the breast, non-melanomatous carcinoma of the skin, is allowed, as is history of other invasive malignancy that is in remission for >/=  years after treatment with curative intent
+Uncontrolled prior invasive malignancy, excluding the current diagnosis
+Second primary invasive malignancy that has not been in remission for greater than  years.
+History of prior invasive rectal malignancy, regardless of disease-free interval
+Subjects with a history of another invasive malignancy ? years of study drug initiation.
+Other invasive malignancy within the past  years.
+History of another invasive malignancy that has not been in remission for at least  years
+History of a primary invasive malignancy not listed in the inclusion criteria, which has not been in remission for at least  years. The following are exempt from the  year limit:
+History of another invasive cancer within  years of randomization;
+Prior or concurrent invasive malignancy (other than multiple myeloma) within  years of study start
+History of a prior invasive malignancy in past  years
+History of another primary invasive cancer, hematologic malignancy, or myelodysplastic syndrome that has not been in remission for at least  years
+Evidence of other active, invasive malignancy requiring treatment within the past  years; noninvasive cancer history (such as carcinoma-in-situ [CIS] that has been resected) is allowed
+Invasive malignancy other than melanoma at the time of enrollment or within  years prior to first dose of study treatment
+Patients with a history within the last  years of another invasive malignancy.
+Other invasive malignancy within  years
+Participants who have had or are planning to have the following invasive procedures
+History of another primary invasive malignancy that has not been in remission for at least  years
+History of another active invasive primary cancer requiring ongoing treatment
+Other invasive malignancy within  years
+Invasive or active malignancy in past  years
+No invasive tumors within the last  years unless confined to an organ (e.g. prostate or thyroid cancer) and treated with curative therapy (e.g. surgery and/or radiation); please note, there must be no evidence of the prior malignancy using standard criteria to evaluate the specific prior malignancy
+Prior invasive malignancy of other histology currently requiring treatment
+Invasive malignancy or history of invasive malignancy other than disease under study: any other invasive malignancy from which the subject has been disease-free for more than  years and, in the opinion of the principal investigator and GSK Medical Monitor, will not affect the evaluation of the effects of this clinical trial treatment on currently targeted malignancy, can be included in this clinical trial; Curatively treated non-melanoma skin cancer and any carcinoma-in-situ.
+Patients with prior invasive malignancy within two years of enrollment are excluded
+Other active, invasive malignancy requiring ongoing therapy or expected to require systemic therapy
+Invasive malignancy or history of invasive malignancy other than disease under study within the last two years except: Any other invasive malignancy for which the subject was definitively treated, has been disease-free for <= years and in the opinion of the principal investigator and GSK Medical Monitor will not affect the evaluation of the effects of the study treatment on the currently targeted malignancy, may be included in this clinical trial; and curatively treated non-melanoma skin cancer.
+Any prior invasive malignancy within  years before randomization
+No evidence of disease (in situ or invasive cancer that would normally be treated by resection) at trial entry as determined by the investigator; diagnosis of invasive cancer must be at least  years prior to initiation on trial
+History of invasive carcinoma =<  years (except subjects with Dukes A/B carcinoma =<  years prior to pre-registration or any stage of colon cancer if >=  years post surgical resection)
+Subjects must not have another active invasive malignancy, with the following exceptions and notes:
+Second primary invasive malignancy that has not been in remission for greater than  years.